The cancer cell secretome: A good source for discovering biomarkers?

Journal of Proteomics

Volumn 73, Issue 10, 2010, Pages 1896-1906

  Pavlou, Maria P ^a,b   Diamandis, Eleftherios P ^a,b,c  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Cancer biomarkers; Mass spectrometry; Proteomic analysis; Proximal fluids; Secretome; Tissue culture

Indexed keywords

ALPHA ENOLASE; APOLIPOPROTEIN E; BETA1 INTEGRIN; BIOLOGICAL MARKER; CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CATHEPSIN D; CD9 ANTIGEN; CHEMOKINE; FOLLISTATIN; GALECTIN 3; GELATINASE B; GLUTATHIONE TRANSFERASE; HEAT SHOCK PROTEIN 70; LACTATE DEHYDROGENASE; LACTATE DEHYDROGENASE B CHAIN; MITOCHONDRIAL CREATINE KINASE; PEPTIDES AND PROTEINS; PERLECAN; PHOSPHOGLYCERATE KINASE; PROSTATE SPECIFIC ANTIGEN; PROTEIN DMBT1; SECRETOME; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 2; STROMAL CELL DERIVED FACTOR 4; TRANSFERRIN; TRIOSEPHOSPHATE ISOMERASE; TUMOR PROTEIN; UNCLASSIFIED DRUG; VITAMIN D BINDING PROTEIN;

BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; COLORECTAL CANCER; HUMAN; LUNG CANCER; PANCREAS CANCER; PLEURA EFFUSION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN SECRETION; PROTEOMICS; REVIEW;

BREAST NEOPLASMS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; EARLY DIAGNOSIS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASMS; PANCREATIC NEOPLASMS; PROSTATIC NEOPLASMS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 77956419405     PISSN: 18743919     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jprot.2010.04.003     Document Type: Review

References (83)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
2. Etzioni R., Urban N., Ramsey S., McIntosh M., Schwartz S., Reid B., et al. The case for early detection. Nat Rev Cancer 2003, 3:243-252.
3. Khatcheressian J.L., Wolff A.C., Smith T.J., Grunfeld E., Muss H.B., Vogel V.G., et al. American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol 2006, 24:5091-5097.
4. Anderson N.L., Anderson N.G. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002, 1:845-867.
5. Omenn G.S., States D.J., Adamski M., Blackwell T.W., Menon R., Hermjakob H., et al. Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics 2005, 5:3226-3245.
6. Tjalsma H., Bolhuis A., Jongbloed J.D., Bron S., van Dijl J.M. Signal peptide-dependent protein transport in Bacillus subtilis: a genome-based survey of the secretome. Microbiol Mol Biol Rev 2000, 64:515-547.
7. Volmer M.W., Stuhler K., Zapatka M., Schoneck A., Klein-Scory S., Schmiegel W., et al. Differential proteome analysis of conditioned media to detect Smad4 regulated secreted biomarkers in colon cancer. Proteomics 2005, 5:2587-2601.
8. Diamandis E.P. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Mol Cell Proteomics 2004, 3:367-378.
9. Veenstra T.D., Conrads T.P., Hood B.L., Avellino A.M., Ellenbogen R.G., Morrison R.S. Biomarkers: mining the biofluid proteome. Mol Cell Proteomics 2005, 4:409-418.
10. Qian W.J., Jacobs J.M., Liu T., Camp D.G., Smith R.D. Advances and challenges in liquid chromatography-mass spectrometry-based proteomics profiling for clinical applications. Mol Cell Proteomics 2006, 5:1727-1744.
11. Koomen J.M., Haura E.B., Bepler G., Sutphen R., Remily-Wood E.R., Benson K., et al. Proteomic contributions to personalized cancer care. Mol Cell Proteomics 2008, 7:1780-1794.
12. Edwards B.K., Brown M.L., Wingo P.A., Howe H.L., Ward E., Ries L.A., et al. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 2005, 97:1407-1427.
13. Kulpa J., Wojcik E., Radkowski A., Kolodziejski L., Stasik Z. CYFRA 21-1, TPA-M, TPS, SCC-Ag and CEA in patients with squamous cell lung cancer and in chemical industry workers as a reference group. Anticancer Res 2000, 20:5035-5040.
14. Molina R., Filella X., Auge J.M. ProGRP: a new biomarker for small cell lung cancer. Clin Biochem 2004, 37:505-511.
15. Bonner J.A., Sloan J.A., Rowland K.M., Klee G.G., Kugler J.W., Mailliard J.A., et al. Significance of neuron-specific enolase levels before and during therapy for small cell lung cancer. Clin Cancer Res 2000, 6:597-601.
16. Schneider J. Tumor markers in detection of lung cancer. Adv Clin Chem 2006, 42:1-41.
17. Sung H.J., Cho J.Y. Biomarkers for the lung cancer diagnosis and their advances in proteomics. BMB Rep 2008, 41:615-625.
18. Andrews C.O., Gora M.L. Pleural effusions: pathophysiology and management. Ann Pharmacother 1994, 28:894-903.
19. DeCamp M.M., Mentzer S.J., Swanson S.J., Sugarbaker D.J. Malignant effusive disease of the pleura and pericardium. Chest 1997, 112:291S-295S.
20. Xiao T., Ying W., Li L., Hu Z., Ma Y., Jiao L., et al. An approach to studying lung cancer-related proteins in human blood. Mol Cell Proteomics 2005, 4:1480-1486.
21. Lou X., Xiao T., Zhao K., Wang H., Zheng H., Lin D., et al. Cathepsin D is secreted from M-BE cells: its potential role as a biomarker of lung cancer. J Proteome Res 2007, 6:1083-1092.
22. Chen Y., Zhang H., Xu A., Li N., Liu J., Liu C., et al. Elevation of serum l-lactate dehydrogenase B correlated with the clinical stage of lung cancer. Lung Cancer 2006, 54:95-102.
23. Kim J.E., Koo K.H., Kim Y.H., Sohn J., Park Y.G. Identification of potential lung cancer biomarkers using an in vitro carcinogenesis model. Exp Mol Med 2008, 40:709-720.
24. Huang L.J., Chen S.X., Huang Y., Luo W.J., Jiang H.H., Hu Q.H., et al. Proteomics-based identification of secreted protein dihydrodiol dehydrogenase as a novel serum markers of non-small cell lung cancer. Lung Cancer 2006, 54:87-94.
25. Wang C.L., Wang C.I., Liao P.C., Chen C.D., Liang Y., Chuang W.Y., et al. Discovery of retinoblastoma-associated binding protein 46 as a novel prognostic marker for distant metastasis in nonsmall cell lung cancer by combined analysis of cancer cell secretome and pleural effusion proteome. J Proteome Res 2009, 8:4428-4440.
26. Planque C., Kulasingan V., Smith C.R., Reckamp K., Goodglick L., Diamandis E.P. Identification of five candidate lung cancer biomarkers by proteomic analysis of conditioned media of four lung cancer cell lines. Mol Cell Proteomics 2009.
27. Tyan Y.C., Wu H.Y., Lai W.W., Su W.C., Liao P.C. Proteomic profiling of human pleural effusion using two-dimensional nano liquid chromatography tandem mass spectrometry. J Proteome Res 2005, 4:1274-1286.
28. Soltermann A., Ossola R., Kilgus-Hawelski S., von Eckardstein A., Suter T., Aebersold R., et al. N-glycoprotein profiling of lung adenocarcinoma pleural effusions by shotgun proteomics. Cancer 2008, 114:124-133.
29. Barry M.J. Screening for prostate cancer - the controversy that refuses to die. N Engl J Med 2009, 360:1351-1354.
30. Punglia R.S., D'Amico A.V., Catalona W.J., Roehl K.A., Kuntz K.M. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med 2003, 349:335-342.
31. Sardana G., Dowell B., Diamandis E.P. Emerging biomarkers for the diagnosis and prognosis of prostate cancer. Clin Chem 2008, 54:1951-1960.
32. Ramirez M.L., Nelson E.C., Evans C.P. Beyond prostate-specific antigen: alternate serum markers. Prostate Cancer Prostatic Dis 2008, 11:216-229.
33. Pilch B., Mann M. Large-scale and high-confidence proteomic analysis of human seminal plasma. Genome Biol 2006, 7:R40.
34. Sardana G., Jung K., Stephan C., Diamandis E.P. Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers. J Proteome Res 2008, 7:3329-3338.
35. Pang B., Zhang H., Wang J., Chen W.Z., Li S.H., Shi Q.G., et al. Ubiquitous mitochondrial creatine kinase is overexpressed in the conditioned medium and the extract of LNCaP lineaged androgen independent cell lines and facilitates prostate cancer progression. Prostate 2009, 69:1176-1187.
36. Martin D.B., Gifford D.R., Wright M.E., Keller A., Yi E., Goodlett D.R., et al. Quantitative proteomic analysis of proteins released by neoplastic prostate epithelium. Cancer Res 2004, 64:347-355.
37. Sorlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001, 98:10869-10874.
38. Sturgeon C.M., Duffy M.J., Stenman U.H., Lilja H., Brunner N., Chan D.W., et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem 2008, 54:e11-e79.
39. Malatesta M., Mannello F., Bianchi G., Sebastiani M., Gazzanelli G. Biochemical and ultrastructural features of human milk and nipple aspirate fluids. J Clin Lab Anal 2000, 14:330-335.
40. Petrakis N.L. Physiologic, biochemical, and cytologic aspects of nipple aspirate fluid. Breast Cancer Res Treat 1986, 8:7-19.
41. Kulasingam V., Diamandis E.P. Proteomics analysis of conditioned media from three breast cancer cell lines: a mine for biomarkers and therapeutic targets. Mol Cell Proteomics 2007, 6:1997-2011.
42. Kulasingam V., Zheng Y., Soosaipillai A., Leon A.E., Gion M., Diamandis E.P. Activated leukocyte cell adhesion molecule: a novel biomarker for breast cancer. Int J Cancer 2009, 125:9-14.
43. Mbeunkui F., Metge B.J., Shevde L.A., Pannell L.K. Identification of differentially secreted biomarkers using LC-MS/MS in isogenic cell lines representing a progression of breast cancer. J Proteome Res 2007, 6:2993-3002.
44. Colzani M., Waridel P., Laurent J., Faes E., Ruegg C., Quadroni M. Metabolic labeling and protein linearization technology allow the study of proteins secreted by cultured cells in serum-containing media. J Proteome Res 2009, 8:4779-4788.
45. Lawlor K., Nazarian A., Lacomis L., Tempst P., Villanueva J. Pathway-based biomarker search by high-throughput proteomics profiling of secretomes. J Proteome Res 2009, 8:1489-1503.
46. Noble J.L., Dua R.S., Coulton G.R., Isacke C.M., Gui G.P. A comparative proteinomic analysis of nipple aspiration fluid from healthy women and women with breast cancer. Eur J Cancer 2007, 43:2315-2320.
47. Kuerer H.M., Goldknopf I.L., Fritsche H., Krishnamurthy S., Sheta E.A., Hunt K.K. Identification of distinct protein expression patterns in bilateral matched pair breast ductal fluid specimens from women with unilateral invasive breast carcinoma. High-throughput biomarker discovery. Cancer 2002, 95:2276-2282.
48. Pawlik T.M., Fritsche H., Coombes K.R., Xiao L., Krishnamurthy S., Hunt K.K., et al. Significant differences in nipple aspirate fluid protein expression between healthy women and those with breast cancer demonstrated by time-of-flight mass spectrometry. Breast Cancer Res Treat 2005, 89:149-157.
49. Li J., Zhao J., Yu X., Lange J., Kuerer H., Krishnamurthy S., et al. Identification of biomarkers for breast cancer in nipple aspiration and ductal lavage fluid. Clin Cancer Res 2005, 11:8312-8320.
50. Paweletz C.P., Trock B., Pennanen M., Tsangaris T., Magnant C., Liotta L.A., et al. Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF: potential for new biomarkers to aid in the diagnosis of breast cancer. Dis Markers 2001, 17:301-307.
51. He J., Gornbein J., Shen D., Lu M., Rovai L.E., Shau H., et al. Detection of breast cancer biomarkers in nipple aspirate fluid by SELDI-TOF and their identification by combined liquid chromatography-tandem mass spectrometry. Int J Oncol 2007, 30:145-154.
52. Pawlik T.M., Hawke D.H., Liu Y., Krishnamurthy S., Fritsche H., Hunt K.K., et al. Proteomic analysis of nipple aspirate fluid from women with early-stage breast cancer using isotope-coded affinity tags and tandem mass spectrometry reveals differential expression of vitamin D binding protein. BMC Cancer 2006, 6:68.
53. Varnum S.M., Covington C.C., Woodbury R.L., Petritis K., Kangas L.J., Abdullah M.S., et al. Proteomic characterization of nipple aspirate fluid: identification of potential biomarkers of breast cancer. Breast Cancer Res Treat 2003, 80:87-97.
54. Alexander H., Stegner A.L., Wagner-Mann C., Du Bois G.C., Alexander S., Sauter E.R. Proteomic analysis to identify breast cancer biomarkers in nipple aspirate fluid. Clin Cancer Res 2004, 10:7500-7510.
55. Geenen J.E., Schmitt M.G., Wu W.C., Hogan W.J. Major complications of coloscopy: bleeding and perforation. Am J Dig Dis 1975, 20:231-235.
56. Winawer S., Fletcher R., Rex D., Bond J., Burt R., Ferrucci J., et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale - update based on new evidence. Gastroenterology 2003, 124:544-560.
57. Booth R.A. Minimally invasive biomarkers for detection and staging of colorectal cancer. Cancer Lett 2007, 249:87-96.
58. Bruinvels D.J., Stiggelbout A.M., Kievit J., van Houwelingen H.C., Habbema J.D., van de Velde C.J. Follow-up of patients with colorectal cancer. A meta-analysis. Ann Surg 1994, 219:174-182.
59. Choi D.S., Lee J.M., Park G.W., Lim H.W., Bang J.Y., Kim Y.K., et al. Proteomic analysis of microvesicles derived from human colorectal cancer cells. J Proteome Res 2007, 6:4646-4655.
60. Shi H.J., Stubbs R., Hood K. Characterization of de novo synthesized proteins released from human colorectal tumour explants. Electrophoresis 2009, 30:2442-2453.
61. Wu C.C., Chen H.C., Chen S.J., Liu H.P., Hsieh Y.Y., Yu C.J., et al. Identification of collapsin response mediator protein-2 as a potential marker of colorectal carcinoma by comparative analysis of cancer cell secretomes. Proteomics 2008, 8:316-332.
62. Thery C., Zitvogel L., Amigorena S. Exosomes: composition, biogenesis and function. Nat Rev Immunol 2002, 2:569-579.
63. Xue H., Lu B., Zhang J., Wu M., Huang Q., Wu Q., et al. Identification of serum biomarkers for colorectal cancer metastasis using a differential secretome approach. J Proteome Res 2010, 9:545-555.
64. Pleskow D.K., Berger H.J., Gyves J., Allen E., McLean A., Podolsky D.K. Evaluation of a serologic marker, CA19-9, in the diagnosis of pancreatic cancer. Ann Intern Med 1989, 110:704-709.
65. Akdogan M., Sasmaz N., Kayhan B., Biyikoglu I., Disibeyaz S., Sahin B. Extraordinarily elevated CA19-9 in benign conditions: a case report and review of the literature. Tumori 2001, 87:337-339.
66. Ni X.G., Bai X.F., Mao Y.L., Shao Y.F., Wu J.X., Shan Y., et al. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. Eur J Surg Oncol 2005, 31:164-169.
67. Chen R., Pan S., Brentnall T.A., Aebersold R. Proteomic profiling of pancreatic cancer for biomarker discovery. Mol Cell Proteomics 2005, 4:523-533.
68. Gronborg M., Kristiansen T.Z., Iwahori A., Chang R., Reddy R., Sato N., et al. Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach. Mol Cell Proteomics 2006, 5:157-171.
69. Gronborg M., Kristiansen T.Z., Iwahori A., Chang R., Reddy R., Sato N., et al. Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach. Mol Cell Proteomics 2006, 5:157-171.
70. Chen R., Pan S., Yi E.C., Donohoe S., Bronner M.P., Potter J.D., et al. Quantitative proteomic profiling of pancreatic cancer juice. Proteomics 2006, 6:3871-3879.
71. Chen R., Pan S., Cooke K., Moyes K.W., Bronner M.P., Goodlett D.R., et al. Comparison of pancreas juice proteins from cancer versus pancreatitis using quantitative proteomic analysis. Pancreas 2007, 34:70-79.
72. Rosty C., Christa L., Kuzdzal S., Baldwin W.M., Zahurak M.L., Carnot F., et al. Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res 2002, 62:1868-1875.
73. Sasaki K., Sato K., Akiyama Y., Yanagihara K., Oka M., Yamaguchi K. Peptidomics-based approach reveals the secretion of the 29-residue COOH-terminal fragment of the putative tumor suppressor protein DMBT1 from pancreatic adenocarcinoma cell lines. Cancer Res 2002, 62:4894-4898.
74. Cheung W., Darfler M.M., Alvarez H., Hood B.L., Conrads T.P., Habbe N., et al. Application of a global proteomic approach to archival precursor lesions: deleted in malignant brain tumors 1 and tissue transglutaminase 2 are upregulated in pancreatic cancer precursors. Pancreatology 2008, 8:608-616.
75. Tian M., Cui Y.Z., Song G.H., Zong M.J., Zhou X.Y., Chen Y., et al. Proteomic analysis identifies MMP-9, DJ-1 and A1BG as overexpressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients. BMC Cancer 2008, 8:241.
76. Gorg A., Obermaier C., Boguth G., Harder A., Scheibe B., Wildgruber R., et al. The current state of two-dimensional electrophoresis with immobilized pH gradients. Electrophoresis 2000, 21:1037-1053.
77. Kim J.H., Skates S.J., Uede T., Wong K.K., Schorge J.O., Feltmate C.M., et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 2002, 287:1671-1679.
78. Dowling P., O'Driscoll L., Meleady P., Henry M., Roy S., Ballot J., et al. 2-D difference gel electrophoresis of the lung squamous cell carcinoma versus normal sera demonstrates consistent alterations in the levels of ten specific proteins. Electrophoresis 2007, 28:4302-4310.
79. Diamandis E.P. Serum proteomic profiling by matrix-assisted laser desorption-ionization time-of-flight mass spectrometry for cancer diagnosis: next steps. Cancer Res 2006, 66:5540-5541.
80. Diamandis E.P. Point: Proteomic patterns in biological fluids: do they represent the future of cancer diagnostics?. Clin Chem 2003, 49:1272-1275.
81. Diamandis E.P. Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J Natl Cancer Inst 2004, 96:353-356.
82. Chen X., Sun L., Yu Y., Xue Y., Yang P. Amino acid-coded tagging approaches in quantitative proteomics. Expert Rev Proteomics 2007, 4:25-37.
83. Flory M.R., Griffin T.J., Martin D., Aebersold R. Advances in quantitative proteomics using stable isotope tags. Trends Biotechnol 2002, 20:S23-S29.